Bragar Eagel & Squire, P.C. is Investigating Zogenix, Inc. (ZGNX) on Behalf of Stockholders and Encourages ZGNX Investors to Contact the Firm
NEW YORK, April 10, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Zogenix, Inc. (NASDAQ: ZGNX). Our investigation concerns whether Zogenix has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On April 8, 2019, Zogenix announced receipt of a Refusal To File letter from the U.S. FDA regarding its New Drug Application (“NDA”) for FINTEPLA, the company’s proposed treatment for seizures associated with Dravet syndrome. Zogenix advised investors that “the FDA determined that the NDA . . . was not sufficiently completed to permit a substantive review. . . . [F]irst, certain non-clinical studies were not submitted to allow assessment of the chronic administration of fenfluramine; and, second, the application contained an incorrect version of a clinical dataset, which prevented the completion of the review process that is necessary to support the filing of the NDA.”
On this news, Zogenix’s share price fell by more than 23%, closing at $39.96 per share on April 9, 2019.
If you purchased or otherwise acquired Zogenix shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Zogenix please go to http://www.bespc.com/zgnx. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.